Bernd Muehlenweg

SVP, Head of Global Business Development, Cell Therapy - Global BD iPSC Cell Therapy at Evotec

Speaker

Bernd Muehlenweg has a wealth of experience in senior positions focusing on business and corporate development and alliance management in the pharmaceutical and biotechnology industries. He has been involved in establishing a broad bandwidth of collaborations to develop and commercialize assets from early-stage to late-stage clinical development. Bernd also founded Panoptes Pharma GmbH, a biotechnology start-up that was acquired by a Nasdaq-listed company. He currently serves as Senior Vice President of Global Business Development, Cell Therapy at Evotec. Before this, Bernd held the position of Chief Business Officer, Member of the Executive Board, at Nanobiotix, a French clinical-stage oncology company. Building sustainable and durable partnerships to advance innovative approaches into approved medications has been driving him throughout his career.